Integrating GLP-1 RAs in T2D and CKD care

CE / CME

Integrating GLP-1 RAs Into T2D and CKD Management

Physician Assistants/Physician Associates: 0.50 AAPA Category 1 CME credit

Nurses: 0.50 Nursing contact hour

Physicians: maximum of 0.50 AMA PRA Category 1 Credit

Released: December 12, 2024

Expiration: December 11, 2025

David Charytan
David Charytan, MD, MSc
Jennifer B Green
Jennifer B Green, MD

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

GLP-1 RAs are thought to reduce the risk of CKD through which of the following mechanisms?

2.

In an individual with T2D and CKD already taking a RAAS inhibitor and an SGLT2 inhibitor, which of the following would be most appropriate to recommend to further reduce their risk of renal disease progression?

3.

A patient with T2D, high-risk ASCVD, and CKD is managed on metformin and dapagliflozin. Their A1C remains elevated at 8.5%. Which of the following medications should be recommended to optimize their treatment?

4.

Up to now, how likely were you to recommend GLP-1 RAs for kidney risk reduction in patients with T2D?